Biological Activity

Bulevirtide is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection. Bulevirtide prevents Hepatitis D entry into cells. It is effective in the reduction of Hepatitis D virus (HDV) RNA levels and improvement of liver inflammation in cases of Hepatitis D infection. In rats, bulevirtide administered by subcutaneous injection is rapidly absorbed with a Cmax of 4 to 6 hours.

Product Citations

• 

  Int J Biol Macromol. 2023 Jun 22;245:125539.

  Strongylocentrotus nudus egg polysaccharide (SEP) suppresses HBV replication via activation of TLR4-induced immune pathway
  Bulevirtide purchased from AbMole

Chemical Information

CAS Number	2012558-47-1
Storage	Powder          -20°C   3 years ;  4°C   2 years In solvent       -80°C   6 months ;  -20°C   1 month

References

[1] Ahmed Ghallab, et al. J Hepatol. Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity

[2] Lena Allweiss, et al. Gut. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo

[3] Tassilo Volz, et al. J Hepatol. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus

[4] Shirin Nkongolo, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect]

[5] D Yardeni, et al. Drugs Today (Barc). Bulevirtide for HBV and HDV infections

[6] Connie Kang, et al. Drugs. Bulevirtide: First Approval

[7] Christopher Koh, et al. Clin Liver Dis. HBV/HDV Coinfection: A Challenge for Therapeutics

[8] Karin Wisskirchen, et al. J Clin Invest. T cell receptor grafting allows virological control of Hepatitis B virus infection